Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
Cemiplimab
Regeneron UK Limited
Lung Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Hormone Receptor-positive Breast Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Advanced Cancer
1 trial -
Cemiplimab
Regeneron UK Limited
Anaplastic Thyroid Cancer
1 trial -
Cemiplimab-Rwlc
Regeneron UK Limited
Merkel Cell Carcinoma
1 trial -
Chemophase
HALOZYME THERAPEUTICS, INC.
Superficial Bladder Cancer
1 trial -
Chimeric antigen receptor T cell
The First People's Hospital of Lianyungang
Pancreatic Cancer
1 trial -
Ciforadenant
Corvus Pharmaceuticals
Renal Cell Cancer
1 trial -
Cisplatin
BioMarin Pharmaceutical Australia Pty Ltd
Solid Tumors
1 trial -
Cisplatin
Regeneron UK Limited
Head and Neck Cancer
1 trial -
Cisplatin
AstraZeneca
Inoperable Locally Advanced or Metastatic Biliary Tract Cancer
1 trial -
Cisplatin
United Therapeutics Europe Ltd
Advanced Cholangiocarcinoma
1 trial -
Click-cleavable imaging in HER2-positive cancers (CleavHER trial).
Disc Medicine
HER2-positive tumors
1 trial -
Clifutinib Besylate
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Myeloid Leukemia
1 trial -
Clifutinib with fed state
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Acute Myeloid Leukemia in Children
1 trial -
Cobimetinib
Cardiff Oncology
Locally Advanced Pancreatic Ductal Adenocarcinoma
1 trial -
Comparison between ABP 234 and Keytruda® (Pembrolizumab)
Amgen
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
1 trial -
Concurrent chemotherapy
Sun Yat-sen University
Locally Advanced Lung Carcinoma
1 trial -
Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma (DLBCL)
1 trial -
Control Group
Tvardi Therapeutics
Squamous Cell Carcinoma of Head and Neck
1 trial -
Cosibelimab
TG THERAPEUTICS, INC.
B-cell Non Hodgkin Lymphoma
1 trial -
Custirsen, paclitaxel and carboplatin
Teva Pharma GmbH
Cancer
1 trial -
Cyclophosphamide
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Locally Advanced Melanoma
1 trial -
Cyclophosphamide
Nektar Therapeutics UK Limited
Recurrent Diffuse Large B-Cell Lymphoma
1 trial -
Cyclophosphamide and Fludarabine
Chongqing Precision Biotech Co., Ltd
Lung Cancer, Nonsmall Cell, Recurrent
1 trial -
D-FR-60010-015
Ipsen
Metastatic Pancreatic Adenocarcinoma
1 trial -
D0816C00025
AstraZeneca AB
solid tumors
1 trial -
D702EC00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D8530C00001
AstraZeneca AB
"Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"
1 trial -
D8990C00001
AstraZeneca AB
Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.
1 trial -
D8991C00002
AstraZeneca AB
Ovarian cancer Primary peritoneal cancer Fallopian tube cancer
1 trial -
D907HC00001
AstraZeneca AB
• Non-small cell lung cancer (Stage III, unresectable) • Small cell lung cancer (Limited stage) • Hepatocellular carcinoma (Unresectable) • Advanced or Metastatic non-small cell lung cancer
1 trial -
D926FC00001
AstraZeneca AB
Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
1 trial -
D933IC00001
AstraZeneca AB
Metastatic Non-Small Cell Lung Cancer (NSCLC)
1 trial -
D9470C00001
AstraZeneca AB
CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.
1 trial -
D967JC00002
AstraZeneca AB
Metastatic Breast Cancer
1 trial -
D967YC00001
AstraZeneca AB
Advanced or metastatic non-squamous non-small lung cancer (mNSCLC) with human epidermal growth factor receptor 2 (HER2) overexpression (OE)
1 trial -
DCVac-L
NORTHWEST BIOTHERAPEUTICS INC
Ovarian Cancer
1 trial -
DHAP
Takeda
Hodgkin Lymphoma
1 trial -
DPH001-01
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
DPH001-01
Lacuna Pharma Pty Ltd
Hepatocellular carcinoma, renal cell carcinoma and differentiated thyroid carcinoma.
1 trial -
DS-1205c
Daiichi Sankyo
Non-small Cell Lung Cancer (NSCLC)
1 trial -
DS1062-A-U102
Daiichi Sankyo
Non-small cell lung cancer
1 trial -
DS3201-324
Daiichi Sankyo
This study will be a Phase 1b, global, multicenter, open-label, 2-part study of valemetostat in combination with DXd ADCs. The Master Protocol study design contains independent subprotocols, which have been defined by treatment combination and subject population, as follows: Sub-protocol A: Valemetostat in combination with T-DXd in subjects with previously treated, unresectable and/or metastatic HER2-low (immunohistochemistry[IHC] 1+ or IHC 2+/in situ hybridization [ISH]-negative) BC; for details, see Sub-protocol A. Sub-protocol B: Valemetostat in combination with T-DXd in subjects with previously treated, advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma; for details, see Sub-protocol B. Sub-protocol C: Valemetostat in combination with Dato-DXd in subjects with previously treated, locally advanced, unresectable, or metastatic non-squamous NSCLC with or without actionable genomic alteration(s); for details, see Sub-protocol C.
1 trial -
DS8201-A-U106
Daiichi Sankyo
Locally advanced/metastatic breast or non-small cell lung cancer
1 trial -
DT2216
United Therapeutics Europe Ltd
Ovarian Cancer
1 trial -
Darlifarnib
Kura Oncology
Solid Tumors With HRAS Alterations
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.